- Home
- SOAR vs ONVO Comparison
SOAR vs ONVO Comparison
Compare SOAR & ONVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOAR
- ONVO
- Stock Information
- Founded
- SOAR 2021
- ONVO 2007
- Country
- SOAR United States
- ONVO United States
- Employees
- SOAR N/A
- ONVO N/A
- Industry
- SOAR Blank Checks
- ONVO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SOAR Finance
- ONVO Health Care
- Exchange
- SOAR Nasdaq
- ONVO Nasdaq
- Market Cap
- SOAR 5.5M
- ONVO 5.3M
- IPO Year
- SOAR N/A
- ONVO N/A
- Fundamental
- Price
- SOAR $0.15
- ONVO $0.37
- Analyst Decision
- SOAR
- ONVO
- Analyst Count
- SOAR 0
- ONVO 0
- Target Price
- SOAR N/A
- ONVO N/A
- AVG Volume (30 Days)
- SOAR 7.4M
- ONVO 103.2K
- Earning Date
- SOAR 03-25-2025
- ONVO 02-19-2025
- Dividend Yield
- SOAR N/A
- ONVO N/A
- EPS Growth
- SOAR N/A
- ONVO N/A
- EPS
- SOAR N/A
- ONVO N/A
- Revenue
- SOAR $102,271,000.00
- ONVO $122,000.00
- Revenue This Year
- SOAR N/A
- ONVO $59.08
- Revenue Next Year
- SOAR N/A
- ONVO $18.24
- P/E Ratio
- SOAR N/A
- ONVO N/A
- Revenue Growth
- SOAR 97.25
- ONVO N/A
- 52 Week Low
- SOAR $0.08
- ONVO $0.32
- 52 Week High
- SOAR $4.50
- ONVO $1.74
- Technical
- Relative Strength Index (RSI)
- SOAR 42.13
- ONVO 49.60
- Support Level
- SOAR $0.08
- ONVO $0.33
- Resistance Level
- SOAR $0.26
- ONVO $0.40
- Average True Range (ATR)
- SOAR 0.04
- ONVO 0.03
- MACD
- SOAR -0.00
- ONVO 0.00
- Stochastic Oscillator
- SOAR 38.07
- ONVO 61.25
About SOAR Volato Group Inc.
Volato Group Inc operates an aircraft ownership program, provides ad-hoc charter flights, sells deposit products, and manages aircraft for owners in the private aviation industry. It offers fractional ownership, aircraft management, jet cards, deposit, and charter programs. The company's fractional programs provides flexible hours and a revenue share for owners in a fleet of HondaJets, optimized for missions of up to four passengers.
About ONVO Organovo Holdings Inc.
Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases.